DALACIN-C

This brand name is authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Netherlands, New Zealand, Nigeria, Poland, Romania, Singapore, South Africa, UK.

Active ingredients

The drug DALACIN-C contains one active pharmaceutical ingredient (API):

1	Clindamycin UNII 3U02EL437C - CLINDAMYCIN
	Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome and inhibit the early stages of protein synthesis.
	Read more about Clindamycin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DALACIN C Capsule	MPI, EU: SmPC	Medicines and Medical Devices Safety Authority (NZ)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D10AF01	Clindamycin	D Dermatologicals → D10 Anti-acne preparations → D10A Anti-acne preparations for topical use → D10AF Antiinfectives for treatment of acne
Discover more medicines within D10AF01
G01AA10	Clindamycin	G Genito urinary system and sex hormones → G01 Gynecological antiinfectives and antiseptics → G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS → G01AA Antibiotics
Discover more medicines within G01AA10
J01FF01	Clindamycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FF Lincosamides
Discover more medicines within J01FF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	3138E, 5057E
BR	Câmara de Regulação do Mercado de Medicamentos	522718030075017
CA	Health Products and Food Branch	00030570, 00225851, 00260436, 02060604, 02182866
EE	Ravimiamet	1007503, 1007536, 1007569, 1068915, 1070008, 1070019, 1865101
GB	Medicines & Healthcare Products Regulatory Agency	142164, 185723, 36687, 36692, 39566, 43490, 78168
HK	Department of Health Drug Office	00438, 00485
HR	Agencija za lijekove i medicinske proizvode	HR-H-200113413
IE	Health Products Regulatory Authority	19402, 19486, 19534, 19567, 84786
IL	מִשְׂרַד הַבְּרִיאוּת	33, 3511, 7728
IT	Agenzia del Farmaco	023868021
LT	Valstybinė vaistų kontrolės tarnyba	1010488, 1010489, 1079258, 1079670, 1081829, 1092423
MT	Medicines Authority	MA505/01902, MA505/01903, MA505/01904, MA505/01905, PI1438/09701A, PI1513/01701A, PI908/12402A
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	76372, 84560, 84745
NG	Registered Drug Product Database	04-1260, B4-0845
Switch country to Nigeria in order to find specific presentations of DALACIN-C
NL	Z-Index G-Standaard, PRK	30430, 4685
NZ	Medicines and Medical Devices Safety Authority	1159, 1160
PL	Rejestru Produktów Leczniczych	100016908, 100016914, 100016920, 100016937, 100016943, 100450970, 100461382
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65032001, W65033001
SG	Health Sciences Authority	01502P, 02170P, 09496P
ZA	Health Products Regulatory Authority	C/20.1.1/1, F/20.1.1/169